Bavarian Nordic A/S

Bavarian Nordic A/S is a fully integrated biotechnology company that develops, manufactures, and commercializes vaccines for infectious illnesses and cancer immunotherapies. The company is located in Hellerup, Denmark, and has a manufacturing facility in Kvistgrd as well as another in Hrsholm. The company includes an R&D facility in Martinsried, Germany, as well as offices in Zug, Switzerland, and Morrisville, North Carolina. In its research and development, the company employs viral vectors.

In order to produce sterile vaccines for use in people in compliance with the EU cGMP regulations, Bavarian Nordic runs its own commercial-scale manufacturing facility in Kvistgaard, Denmark. A commercial scale multi-product fill and finish facility for liquid and freeze-dried live virus vaccines is now being added to the facility. This facility will handle formulation, filling, freeze-drying, terminal sterilization of WFI (solvent for freeze-dried products), inspection, and packing. Additionally, a new clean room suite is being constructed, which will considerably improve the multipurpose manufacturing facility's capacity and flexibility by enabling the production of numerous products simultaneously. The new fill and finish facility and clean room suite reduce Bavarian Nordic's reliance on third-party contract manufacturing, establishing Bavarian Nordic as one of the world's only independent manufacturers of live virus vaccines capable of producing a wide range of vaccines.

Bavarian Nordic developed MVA-BN, a non-replicating smallpox and monkeypox vaccine approved in Canada, the European Union, and the United States. The vaccine is being used to combat the 2022 monkeypox outbreak, but concerns over vaccine nationalism and hoarding exist.

Vaccinia-fowlpox-TRICOM is a poxvirus-based technology used in the company's cancer immunotherapies. It can be modified to encode different tumor-associated antigens and formed the basis of the company's lead oncology product candidates.

The company has worked with the NIAID to develop a filovirus vaccine for Ebola and Marburg hemorrhagic fever diseases. In collaboration with Crucell Holland B.V., the company produced the first 400,000 doses of the multivalent MVA-BN Filovirus vaccine and adenoviral vector-based AdVac technology in January 2015. It was approved for medical use in the European Union in July 2020.

Founded: 1994

Headquarters: Hellerup, Denmark

Website: https://bavarian-nordic.com/